New Age Alpha Advisors LLC Has $4.72 Million Position in BioMarin Pharmaceutical Inc. $BMRN

New Age Alpha Advisors LLC reduced its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 30.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 79,431 shares of the biotechnology company’s stock after selling 35,407 shares during the quarter. New Age Alpha Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $4,721,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in BMRN. Activest Wealth Management acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $26,000. Smartleaf Asset Management LLC grew its position in shares of BioMarin Pharmaceutical by 92.5% in the third quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 360 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at about $40,000. Parallel Advisors LLC grew its position in shares of BioMarin Pharmaceutical by 62.2% in the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 295 shares during the last quarter. Finally, V Square Quantitative Management LLC acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $45,000. 98.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on BMRN. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $66.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, May 5th. Barclays increased their target price on shares of BioMarin Pharmaceutical from $80.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright reduced their target price on shares of BioMarin Pharmaceutical from $55.00 to $50.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. Finally, Weiss Ratings cut shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $88.67.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN opened at $54.09 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81. The firm has a 50-day simple moving average of $54.46 and a 200 day simple moving average of $56.28. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $66.28. The stock has a market cap of $10.45 billion, a PE ratio of 39.48, a PEG ratio of 0.41 and a beta of 0.23.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 16,486 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the transaction, the executive vice president owned 79,953 shares in the company, valued at $4,833,958.38. This trade represents a 17.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregory R. Friberg sold 6,326 shares of the firm’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the transaction, the executive vice president owned 37,578 shares of the company’s stock, valued at approximately $2,268,959.64. This represents a 14.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 26,093 shares of company stock valued at $1,555,389. Corporate insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.